Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3228607 | 1.00 | CCNA2 (0.42) | CCNA2CDK2CCNA1SCN9ASCD | |
| SCHEMBL3230328 | 0.84 | HSD11B1 (0.43) | SCN9ASCDHSD11B1NPC1RAB9A | |
| SCHEMBL3230333 | 0.84 | HSD11B1 (0.43) | SCN9ASCDHSD11B1NPC1RAB9A | |
| SCHEMBL3220511 | 0.84 | LMNA (0.41) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3220514 | 0.84 | LMNA (0.41) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3225971 | 0.82 | SCD (0.49) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3225964 | 0.82 | SCD (0.49) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3230839 | 0.81 | SCD (0.41) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3230828 | 0.81 | SCD (0.41) | SCN9ASCDHSD11B1OXTRMCHR2 | |
| SCHEMBL3232931 | 0.81 | SCD (0.42) | SCN9ASCDHSD11B1OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | CCNA2 584/4885CDK2 160/4885CCNA1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.